Linxens and Clayens develop mini-NFC tag for medical devices

▤ Summary

This crucial step takes place during the industrialisation process, using a specialised NFC writing device that ensures constant traceability and increased security against counterfeiting and unauthorised removal. The mini-tag strictly complies with regulatory standards for medical devices and syringes, including the European Directive on Counterfeit Medicines, ensuring complete compatibility with existing inventory or tracking systems. "Global health challenges demand the convergence of technical and clinical expertise, with a growing need for remote monitoring, secure connections, data quality, in an aging population, increasing patient autonomy, and overburdened healthcare services. With this revolutionary mini-tag, Linxens offers a solution that embraces cutting-edge technological advancements, ensuring reliability, enhanced security, and unmatched traceability in the administration of treatments." "Working with Linxens on the integration of this mini-tag marks a significant step towards safer and more traceable medical devices," said Matthieu Besse, R&D Manager at Clayens.

▦ Linked Companies

Linxens

$500M to $1B